TScan Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 6, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 6, 2024
TCRX$0.19+2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
(in thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Cash flows from operating activities: | ||
| Net loss | $(89,218) | $(66,221) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation expense | 5,361 | 5,137 |
| Accretion of marketable securities | (1,072) | - |
| Non-cash interest expense related to note payable | 757 | 260 |
| Stock-based compensation | 5,208 | 4,551 |
| Changes in current assets and liabilities: | ||
| Prepaid expenses and other assets | 985 | (410) |
| Right-of-use assets and lease liabilities, net | 935 | (2,047) |
| Accounts payable | (52) | 528 |
| Accrued expense and other liabilities | 3,853 | 732 |
| Deferred revenue | 11,885 | (9,033) |
| Net cash used in operating activities | (61,358) | (66,503) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (3,146) | (4,225) |
| Purchases of marketable securities | (77,613) | - |
| Proceeds from maturities of marketable securities | 20,000 | - |
| Net cash used in investing activities | (60,759) | (4,225) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock, net of offering costs | 42,414 | - |
| Proceeds from issuance of pre-funded warrants, net of offering costs | 92,318 | - |
| Issuance of common stock under ESPP plan | - | 193 |
| Proceeds from exercise of stock options | 711 | 133 |
| Proceeds from issuance of term loan, net of issuance costs paid to lender | - | 29,354 |
| Payments of debt issuance costs | - | (324) |
| Net cash provided by financing activities | 135,443 | 29,356 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 13,326 | (41,372) |
| Cash, cash equivalents, and restricted cash - beginning of year | 125,064 | 166,436 |
| Cash, cash equivalents, and restricted cash - end of year | $138,390 | $125,064 |
| Summary of cash, cash equivalents and restricted cash reported within the consolidated balance sheets: | ||
| Cash and cash equivalents | 133,359 | 120,027 |
| Restricted cash | 5,031 | 5,037 |
| Total cash, cash equivalents, and restricted cash | $138,390 | $125,064 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | $3,002 | $660 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Lease liability arising from obtaining right-of-use asset | $6,214 | $53,541 |
| Purchase of property and equipment in accounts payable and accrued liabilities | $301 | $444 |
TSCAN THERAPEUTICS, INC.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.